Publications by authors named "S R McCurdy"
Venetoclax with hypomethylating agents (HMA) is the standard of care for acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy and is associated with tumor lysis syndrome (TLS). TLS prophylaxis and the use of Cairo Bishop versus Howard diagnostic criteria are not standardized. Here we report TLS prophylaxis and incidence in a retrospective cohort of 100 consecutive AML patients treated with venetoclax and HMA.
View Article and Find Full Text PDFOf 1.2 million Americans who would benefit from pre-exposure prophylaxis (PrEP), only 36% were prescribed PrEP in 2023. Project HOMES is an ongoing study that evaluates recovery residences for individuals in medication-assisted recovery from opioid use disorder across five Texas cities.
View Article and Find Full Text PDFArticle Synopsis
- Opioid use disorder (OUD) significantly impacts mental and physical health, yet there’s limited research on health comorbidities among those in recovery residences receiving medication for OUD (MOUD).
- A study involving 358 recovery residence residents in Texas from 2021 to 2023 found a high prevalence of mental health issues and physical comorbidities, with anxiety/depression and pain/discomfort being the most common health-related quality of life (HRQoL) problems reported.
- Results showed that most comorbidities negatively impacted HRQoL, particularly affecting the ability to perform usual activities, mobility, and pain/discomfort, while older age correlated with increased HRQoL problems.
Expansion and evaluation of level II and III recovery residences for people taking medications for an opioid use disorder: project HOMES (Housing for MAR Expanded Services) study protocol.
BMJ Open
November 2024
Introduction: As the US continues to battle the opioid epidemic, recovery residences remain valuable services for people in recovery. While there is a growing body of literature describing positive outcomes experienced by people who live in recovery residences, little is known about the experience of people who live in these residences while taking medications for an opioid use disorder (MOUD) as part of their recovery. Thus, this study has three aims: (1) expand the availability of recovery residences that meet the National Alliance for Recovery Residences standards in Texas and serve individuals taking medications for an opioid use disorder as part of their recovery; (2) evaluate recovery residences for people taking MOUD as part of their recovery; and (3) compare the cost-effectiveness of recovery residences to treatment-as-usual.
View Article and Find Full Text PDFArticle Synopsis
- Venetoclax is a potential treatment for patients with acute myeloid leukemia (AML) who can't use anthracycline-based therapies, but it has been linked to heart problems in animal studies.
- A study assessed cardiovascular events in AML patients treated with either venetoclax or anthracyclines, finding that MACE occurred in 17% of the venetoclax group and 12% in the anthracycline group, indicating no significant difference in heart issues between the two treatments.
- The research suggests that patients on venetoclax should have close cardiovascular monitoring, especially early in treatment, due to its potential risks.